ii4sm announces CSI Platform for healthcare and life sciences
The International Institute for the Safety of Medicines Ltd. (ii4sm) is proud to announce the launch of its patent-pending Computable Semantics and Interoperability (CSI) software Platform for the healthcare and life sciences sectors. This unique Platform enables unambiguous and context-rich information exchange, integration and analysis as well as computer-based decision support of healthcare and life sciences data in an unprecedented way.
“The Platform is used to build and power Smart Health Applications – by ii4sm or its clients – generating substantial cost reductions while improving technical, scientific and medical benefits for the pharmaceutical industry, payers, providers, regulators and ultimately patients”, says Dr. Roland Haag, CEO of ii4sm.
ii4sm’s Platform and Smart Health Applications are ideally positioned to make a real difference, as confirmed by US and EU expert reports mentioning the “Lack of a platform for innovative applications, … open and robust platform for software developers to build applications to improve data entry processes, provide decision support, or other functionality” and the fact that “… semantic interoperability is the key factor for realizing a wide range of expected benefits from the implementation of eHealth infrastructures and applications” (President’s Council of Advisors on Science and Technology report, December 2010 and eHealth Strategies report, January 2011, respectively).
Improving healthcare efficiency with innovative IT solutions is key to curbing spiraling costs. As an example, the US could save about $78 billion annually (source) with the adoption of efficient, meaningful and context-rich information exchange. There is a declared need for better communication, especially for the automated exchange of contextual patient data, and for avoidance of the current ambiguity in medical terms.
The CSI Platform applies innovative ontology-driven information models that maintain the context of life science and healthcare data across applications in a system-independent way. The CSI Platform captures data within context and allows powerful reasoning capabilities, supporting a flexible, scalable, easily configurable and low-maintenance software development environment.
The Platform and its Applications provide the following technical, medical, and business benefits:
- Dramatically reduced costs in healthcare and life sciences, thanks to efficient applications in drug development, drug safety, providers and payers operations, etc., strongly automating processes and extracting value from context-rich data
- Computer-based decision support enabled by cutting edge semantics infrastructure
- Reduced time and effort to develop custom applications; greatly reduced costs to maintain, adapt, and enhance applications after initial deployment
- Better compliance with standards, higher security and less upgrading effort due to configuration vs. customization benefits
- Interoperability among applications resulting in highly efficient health information exchange
- Innovative machine-based data interpretation / reasoning; context-rich reporting and analysis through structured representation of information
“The advantages of innovative computable semantics on the way to real interoperability among IT systems within and between companies, public institutions, and other stakeholders will benefit the exchange of context-rich data to generate new knowledge, perform powerful analyses, and empower computer-based decision support”, says Dr. Dominik Aronsky, CTO of ii4sm.
To learn more about the Platform and its Applications or to schedule a demonstration please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it . For more information on ii4sm and its product portfolio, please visit the website.
About ii4sm:
ii4sm, the Swiss-based International Institute for the Safety of Medicines, develops and markets the Computable Semantics and Interoperability (CSI) Platform and several Smart Health Applications for healthcare and life sciences. ii4sm completes the product portfolio with domain-specific consulting, outsourcing and pharmacovigilance services and acts as independent, neutral information broker. For more information, visit: www.ii4sm.com
http://www.biovalley.ch/content.cfm?nav=4&content=10&command=details&id=16914